In-Licensing
S.L.A. Pharma is looking to expand its product portfolio with novel ways of treating patients suffering from gastrointestinal disorders. We welcome approaches from potential collaborators with opportunities at various stages of clinical development that fit with our strategic focus.
S.L.A. Pharma is looking to expand its product portfolio with novel ways of treating patients suffering from gastrointestinal disorders. We welcome approaches from potential collaborators with opportunities at various stages of clinical development that fit with our strategic focus.
Out-Licensing
S.L.A. Pharma aims to establish strategic alliances that add value to and enhance the commercial potential of our existing product pipeline, and progress developments as quickly as possible from concept to patients.
S.L.A. Pharma aims to establish strategic alliances that add value to and enhance the commercial potential of our existing product pipeline, and progress developments as quickly as possible from concept to patients.
Our Developments
For further information please contact:
Business Development: E / info@slapharma.com
| Development | Therapeutic Area |
| Topical diltiazem | Anal Fissure |
| EPA-FFA | Familial Adenomatous Polyposis |
| Topical metronidazole | Perianal Crohn's disease |
| Oral naloxone | Opioid induced constipation |
For further information please contact:
Business Development: E / info@slapharma.com